\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Associated Publications}{}% 5
\BOOKMARK [0][-]{chapter*.7}{Contents}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Figures}{}% 7
\BOOKMARK [0][-]{chapter*.10}{List of Tables}{}% 8
\BOOKMARK [0][-]{chapter*.11}{Abbreviations}{}% 9
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 10
\BOOKMARK [1][-]{section.1.1}{Psoriasis and psoriatic arthritis}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.1.1}{Epidemiology and global impact}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.2}{Psoriasis and inflammatory dermatoses}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.3}{PsA and spondyloarthropaties}{section.1.1}% 14
\BOOKMARK [1][-]{section.1.2}{Pathophysiology of psoriasis and psoriatic arthritis}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.2.1}{Clinical presentation and diagnosis}{section.1.2}% 16
\BOOKMARK [2][-]{subsection.1.2.2}{Aetiology of psoriasis and PsA}{section.1.2}% 17
\BOOKMARK [3][-]{subsubsection*.15}{Histopathological alterations in skin and joints}{subsection.1.2.2}% 18
\BOOKMARK [3][-]{subsubsection*.16}{Dysregulation of the innate and adaptive immune response}{subsection.1.2.2}% 19
\BOOKMARK [3][-]{subsubsection*.17}{Environmental factors and disease}{subsection.1.2.2}% 20
\BOOKMARK [2][-]{subsection.1.2.3}{Cell types involved in psoriasis and PsA pathogenesis}{section.1.2}% 21
\BOOKMARK [2][-]{subsection.1.2.4}{Therapeutic intervention and prognosis}{section.1.2}% 22
\BOOKMARK [1][-]{section.1.3}{Genetics of psoriasis and psoriatic arthritis}{chapter.1}% 23
\BOOKMARK [2][-]{subsection.1.3.1}{Heritability}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.2}{Genetic studies}{section.1.3}% 25
\BOOKMARK [3][-]{subsubsection*.19}{Non-GWAS and linkage studies}{subsection.1.3.2}% 26
\BOOKMARK [3][-]{subsubsection*.20}{GWAS}{subsection.1.3.2}% 27
\BOOKMARK [2][-]{subsection.1.3.3}{MHC and non-MHC associations with disease risk}{section.1.3}% 28
\BOOKMARK [2][-]{subsection.1.3.4}{The role of coding and non-coding variants in disease susceptibility}{section.1.3}% 29
\BOOKMARK [2][-]{subsection.1.3.5}{The role of GWAS studies in highlighting disease relevant tissues}{section.1.3}% 30
\BOOKMARK [0][-]{chapter.2}{Material and Methods}{}% 31
\BOOKMARK [1][-]{section.2.1}{Ethical approval and recruitment of study participants}{chapter.2}% 32
\BOOKMARK [2][-]{subsection.2.1.1}{PSO patient recruitment}{section.2.1}% 33
\BOOKMARK [2][-]{subsection.2.1.2}{PsA patient recruitment}{section.2.1}% 34
\BOOKMARK [2][-]{subsection.2.1.3}{Healthy volunteer recruitment}{section.2.1}% 35
\BOOKMARK [1][-]{section.2.2}{Sample processing}{chapter.2}% 36
\BOOKMARK [2][-]{subsection.2.2.1}{PBMC and synovial fluid cells isolation}{section.2.2}% 37
\BOOKMARK [2][-]{subsection.2.2.2}{Primary cell isolation using magnetic-activated cell sorting}{section.2.2}% 38
\BOOKMARK [2][-]{subsection.2.2.3}{Primary cell isolation using fluorescence-activated cell sorting}{section.2.2}% 39
\BOOKMARK [2][-]{subsection.2.2.4}{Skin biopsies processing and adherent assay}{section.2.2}% 40
\BOOKMARK [1][-]{section.2.3}{Experimental protocols}{chapter.2}% 41
\BOOKMARK [2][-]{subsection.2.3.1}{Cryopreservation and cell culture}{section.2.3}% 42
\BOOKMARK [2][-]{subsection.2.3.2}{ATAC-seq, Fast-ATAC and Omni-ATAC}{section.2.3}% 43
\BOOKMARK [2][-]{subsection.2.3.3}{Chromatin Immunoprecipitation with sequencing library preparation by Tn5 transposase}{section.2.3}% 44
\BOOKMARK [2][-]{subsection.2.3.4}{Nucleic acids extraction and RNA-seq}{section.2.3}% 45
\BOOKMARK [3][-]{subsubsection*.25}{Bulk RNA-seq}{subsection.2.3.4}% 46
\BOOKMARK [3][-]{subsubsection*.26}{PsA memory CD4+ and CD8+ single-cell RNA-seq}{subsection.2.3.4}% 47
\BOOKMARK [3][-]{subsubsection*.27}{Small-bulk RNA-seq }{subsection.2.3.4}% 48
\BOOKMARK [2][-]{subsection.2.3.5}{CyTOF}{section.2.3}% 49
\BOOKMARK [0][-]{chapter*.28}{Bibliography}{}% 50
